Dr. Scott Hammer serves as the Harold C. Neu Professor of Medicine, Professor of Epidemiology and Chief of the Division of Infectious Diseases at the Columbia University Medical Center/NewYork-Presbyterian Hospital (CUMC/NYP). His major investigative interest is the treatment and prevention of HIV disease. He is a Principal Investigator (PI) of the NIAID-sponsored Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials Unit. He has been a long-standing investigator in the AIDS Clinical Trials Group (ACTG) and the HIV Vaccine Trials Network (HVTN), chairing a number of major trials including HVTN 505, a phase 2b efficacy study of the Vaccine Research Center’s DNA prime/recombinant adenovirus type 5 vector boost preventive HIV vaccine regimen.
Dr. Hammer is a former Chair of NIAID’s AIDS Vaccine Research Working Group and the Antiviral Products Advisory Committee of the Food and Drug Administration; former leader of the Guidance Development Group for WHO’s antiretroviral guidelines in resource limited settings in 2002, 2003 and 2006; and former Vice Chair of WHO’s Scientific and Technical Advisory Committee on AIDS. He has chaired major international meetings including the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Conference on Retroviruses and Opportunistic Infections (CROI 2015).
Within the HVTN, in addition to protocol leadership, Dr. Hammer has served on a number of scientific committees and is currently a member of the Executive Management Team (EMT) and one of the PI’s of the Leadership and Operations Center (LOC). In this capacity, he will have responsibility for pursuing combination prevention studies and inter-network collaborations in addition to the ongoing duties of an EMT member.